Bone Biologics
- Country
- Ownership
- -
- Employees
- 2
- Market Cap
- -
- Introduction
Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis
- Conditions
- Degenerative Disc DiseaseSpondylolisthesis
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Bone Biologics Corp
- Target Recruit Count
- 30
- Registration Number
- NCT03810573
- Locations
- 🇦🇺
Monash Medical Center, Clayton, Victoria, Australia
🇦🇺St Vincent Melbourne, Fitzroy, Australia
🇦🇺St George Hospital, Kogarah, Australia